Research description

Recombinant Growth Hormone (GH) treatment has been in clinical use since 1985 and over 7000 children in Sweden have been treated since its introduction. It is well known that treatment with GH in childhood improves height, has several metabolic effects in body composition and seems to have a well-tolerated short-term safety profile. However, it is not known what long-term effects this treatment has on the risk of developing morbidity potentially associated with the physiological effects of GH. The aim of our project is to assess these risks both in the short- and long-term.  


PhD, Dept of Women’s and Children’s Health, Karolinska Institute

Karolinska Institute’s Doctoral School for Clinicians in Epidemiology  

Medical School, Karolinska Institute

BA (Fil. kand) in Political Science incl. courses in International Relations, History, Philosophy and Psychology, Stockholm University